Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2Phase 4 1Phase 3 1Phase 2/3 1

Status

Recruiting 3Withdrawn 1Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Hamartoma Syndrome, Multiple 1Autistic Disorder 1

Interventions

Cisplatin 10Gemcitabine 7Fluorouracil 7Carboplatin 7Capecitabine 7venetoclax 6Oxaliplatin 5Cyclophosphamide 4Azacitidine 4sintilimab 3Radiotherapy 3Neoadjuvant Therapy 3Dexamethasone 3Bevacizumab 3130-nm albumin-bound paclitaxel 3trametinib 2regorafenib 2pembrolizumab 2nimotuzumab 2fludarabine 2disitamab vedotin 2daratumumab 2dabrafenib 2camrelizumab 2blinatumomab 2apatinib 2Trastuzumab 2Temozolomide 2Radiotherapy, Intensity-Modulated 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × Everolimus × Clear all
NCT07218575 2026-06-04

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Boston Children's Hospital

Phase 2/3 Not yet recruiting
60 enrolled

Autistic Disorder, Hamartoma Syndrome, Multiple

Data powered by HemOnc (CC BY 4.0) Colophon âš¡